BARINTHUS BIOTHERAPEUTICS PL (BRNS) Stock Price, Quote, News and Overview
NASDAQ:BRNS - Nasdaq - US91864C1071 - ADR - Currency: USD
BRNS Quote, Performance and Key Statistics
1
-0.05 (-5.21%)
The current stock price of BRNS is 1 USD. In the past month the price decreased by -7.41%. In the past year, price decreased by -62.83%.
BRNS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BRNS
Company Profile
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 130 full-time employees. The company went IPO on 2021-04-30. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. The company is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.
Company Info
BARINTHUS BIOTHERAPEUTICS PL
Unit 6-10, Zeus Building, Rutherford Avenue, Harwell
Didcot OXFORDSHIRE GB
Employees: 130
Company Website: https://www.barinthusbio.com/
Investor Relations: http://investors.vaccitech.co.uk
Phone: 441865818808
BARINTHUS BIOTHERAPEUTICS PL / BRNS FAQ
What is the stock price of BARINTHUS BIOTHERAPEUTICS PL today?
The current stock price of BRNS is 1 USD. The price decreased by -5.21% in the last trading session.
What is the ticker symbol for BARINTHUS BIOTHERAPEUTICS PL stock?
The exchange symbol of BARINTHUS BIOTHERAPEUTICS PL is BRNS and it is listed on the Nasdaq exchange.
On which exchange is BRNS stock listed?
BRNS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BARINTHUS BIOTHERAPEUTICS PL stock?
9 analysts have analysed BRNS and the average price target is 5.44 USD. This implies a price increase of 444% is expected in the next year compared to the current price of 1. Check the BARINTHUS BIOTHERAPEUTICS PL stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BARINTHUS BIOTHERAPEUTICS PL worth?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) has a market capitalization of 39.41M USD. This makes BRNS a Nano Cap stock.
How many employees does BARINTHUS BIOTHERAPEUTICS PL have?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) currently has 130 employees.
What are the support and resistance levels for BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) has a support level at 0.99 and a resistance level at 1.05. Check the full technical report for a detailed analysis of BRNS support and resistance levels.
Is BARINTHUS BIOTHERAPEUTICS PL (BRNS) expected to grow?
The Revenue of BARINTHUS BIOTHERAPEUTICS PL (BRNS) is expected to grow by 1093.82% in the next year. Check the estimates tab for more information on the BRNS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BRNS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BRNS, evaluating the profitability, health, valuation and growth aspects
- BARINTHUS BIOTHERAPEUTICS PL (BRNS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BARINTHUS BIOTHERAPEUTICS PL (BRNS) Sales and EPS estimates to see what analysts future expectations are.
- BARINTHUS BIOTHERAPEUTICS PL (BRNS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BARINTHUS BIOTHERAPEUTICS PL (BRNS) Insider and Institutional Ownership to learn about the owners and their transactions.
- BARINTHUS BIOTHERAPEUTICS PL (BRNS) Stock Chart to make your own analysis
- BARINTHUS BIOTHERAPEUTICS PL (BRNS) Latest news and press-releases to stay up to date.
Does BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock pay dividends?
BRNS does not pay a dividend.
When does BARINTHUS BIOTHERAPEUTICS PL (BRNS) report earnings?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) will report earnings on 2025-03-18, after the market close.
What is the Price/Earnings (PE) ratio of BARINTHUS BIOTHERAPEUTICS PL (BRNS)?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.49).
What is the Short Interest ratio of BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?
The outstanding short interest for BARINTHUS BIOTHERAPEUTICS PL (BRNS) is 0.04% of its float. Check the ownership tab for more information on the BRNS short interest.
BRNS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BRNS. When comparing the yearly performance of all stocks, BRNS is a bad performer in the overall market: 88.21% of all stocks are doing better.
BRNS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BRNS. BRNS has a great financial health rating, but its profitability evaluates not so good.
BRNS Financial Highlights
Over the last trailing twelve months BRNS reported a non-GAAP Earnings per Share(EPS) of -1.49. The EPS increased by 26.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.65% | ||
| ROE | -36.3% | ||
| Debt/Equity | 0 |
BRNS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to BRNS. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 16.24% and a revenue growth 1093.82% for BRNS